Alzamend Neuro, Inc.
About Alzamend Neuro, Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$4.5M
- Total assets
- $4.6M
- Market cap
- $4.2M
Source: SEC EDGAR · updated Jun 7, 2026
- Market cap
- $4.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 15, 2021
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review Alzamend Neuro, Inc..